Skip to main content

Table 7 Relation between IMT at baseline and 6-month follow-up after initiation of anti-HCV therapy and the presence of cirrhosis

From: Assessment of carotid atherosclerosis in Egyptian chronic hepatitis C patients after treatment by direct-acting antiviral drugs

   Non-cirrhotic
(no. = 26)
Child A
(no. = 36)
Child B
(no. = 18)
Test valuea p-valuea
  Mean  ± SD Median Mean  ± SD Median Mean  ± SD Median
IMT Baseline 1.18 0.46 0.95 1.17 0.32 1.04 1.46 0.61 1.42 4.75 0.093
6-month follow-up 0.95 0.39 0.76 0.97 0.35 0.90 1.06 0.49 0.88 2.61 0.271
p-valueb    < 0.001  < 0.001 0.001  
  1. p ≤ 0.05 is considered statistically significant; p ≤ 0.01 is considered highly statistically significant. aKruskal-Wallis test. bWilcoxon signed-rank test. SD Standard deviation, IMT Intima-media thickness. IMT at baseline and 6-month follow-up after initiation of anti-HCV therapy and the presence of cirrhosis revealed that there was no significant difference between cirrhotic (neither child A nor B) and non-cirrhotic patients as regards carotid IMT at baseline and after 6-month follow-up. Meanwhile, there was significant decrease in carotid IMT at baseline compared to after 6-month follow-up in the three groups individually